Autor: "Everett BM" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Autorzy:: Htoo PT; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
Tesfaye H; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
Schneeweiss S; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
Wexler DJ; Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, USA.
Everett BM; Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA.
Glynn RJ; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
Schmedt N; Global Epidemiology, Boehringer Ingelheim International GmbH (Germany) DE, Berlin, Germany.
Koeneman L; Global Medical Affairs, Lilly Deutschland GmbH, Bad Homburg, Germany.
Déruaz-Luyet A; Global Epidemiology, Boehringer Ingelheim International GmbH (Germany) DE, Berlin, Germany.
Paik JM; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.; Division of Renal (Kidney) Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Patorno E; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA. .; Pokaż więcej
Źródło:: Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Mar 18; Vol. 23 (1), pp. 103. Date of Electronic Publication: 2024 Mar 18.
Typ publikacji:: Published Erratum

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Autorzy:: Htoo PT; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
Tesfaye H; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
Schneeweiss S; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
Wexler DJ; Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, USA.
Everett BM; Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA.
Glynn RJ; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
Schmedt N; Global Epidemiology, Boehringer Ingelheim International GmbH (Germany) DE, Berlin, Germany.
Koeneman L; Global Medical Affairs, Lilly Deutschland GmbH, Bad Homburg, Germany.
Déruaz-Luyet A; Global Epidemiology, Boehringer Ingelheim International GmbH (Germany) DE, Berlin, Germany.
Paik JM; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.; Division of Renal (Kidney) Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Patorno E; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA. .; Pokaż więcej
Źródło:: Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Feb 08; Vol. 23 (1), pp. 57. Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:: Diabetes Mellitus, Type 2*/diagnosis
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/epidemiology
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Heart Failure*/diagnosis
Heart Failure*/drug therapy
Heart Failure*/epidemiology
Atherosclerosis*/drug therapy
Stroke*/diagnosis
Stroke*/epidemiology
Stroke*/prevention & control
Cardiovascular Diseases*/diagnosis
Cardiovascular Diseases*/epidemiology
Cardiovascular Diseases*/prevention & control
Benzhydryl Compounds*
Glucosides*
Humans ; Aged ; United States ; Adolescent ; Glucagon-Like Peptide-1 Receptor Agonists ; Medicare ; Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia.
Autorzy:: Segar MW; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Cardiology, Texas Heart Institute, Houston, TX, USA.
Khan MS; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Patel KV; Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Vaduganathan M; Brigham and Women's Hospital Heart and Vascular Center, Department of Medicine, Harvard Medical School, Boston, MA, USA.
Kannan V; Clinical Informatics Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Willett D; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Clinical Informatics Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Peterson E; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Tang WHW; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Butler J; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Everett BM; Brigham and Women's Hospital Heart and Vascular Center, Department of Medicine, Harvard Medical School, Boston, MA, USA.
Fonarow GC; Division of Cardiology, Ronald Reagan UCLA Medical Center, Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, CA, USA.
Wang TJ; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
McGuire DK; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Pandey A; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Pokaż więcej
Źródło:: European journal of heart failure [Eur J Heart Fail] 2022 Jan; Vol. 24 (1), pp. 169-180. Date of Electronic Publication: 2021 Nov 23.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Heart Failure*/diagnosis
Heart Failure*/epidemiology
Natriuretic Peptides*
Glucose Metabolism Disorders/*epidemiology
Adult ; Cohort Studies ; Humans ; Risk Assessment/methods ; Risk Factors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Everett BM"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język